Radiation therapy for angiosarcoma of the scalp Treatment outcomes of total scalp irradiation with X-rays and electrons

被引:22
|
作者
Hata, Masaharu [1 ]
Wada, Hidefumi [2 ]
Ogino, Ichiro [3 ]
Omura, Motoko [4 ]
Koike, Izumi [1 ]
Tayama, Yoshibumi [5 ]
Odagiri, Kazumasa [1 ,6 ]
Kasuya, Takeo [1 ]
Inoue, Tomio [1 ]
机构
[1] Yokohama City Univ, Grad Sch Med, Dept Radiol, Yokohama, Kanagawa 2360004, Japan
[2] Yokohama City Univ, Grad Sch Med, Dept Dermatol, Yokohama, Kanagawa 2360004, Japan
[3] Yokohama City Univ, Med Ctr, Dept Radiat Oncol, Yokohama, Kanagawa 2360004, Japan
[4] Shonankamakura Gen Hosp, Dept Radiat Oncol, Kamakura, Kanagawa, Japan
[5] Yokohama Minami Kyousai Hosp, Dept Radiol, Yokohama, Kanagawa, Japan
[6] Yokohama Municipal Citizens Hosp, Dept Radiat Oncol, Yokohama, Kanagawa, Japan
关键词
Angiosarcoma; Interleukin-2; Radiation therapy; Skin neoplasms; Total scalp irradiation; CUTANEOUS ANGIOSARCOMA; RECOMBINANT INTERLEUKIN-2; SOFT-TISSUE; RADIOTHERAPY; IMMUNOTHERAPY; CANCER; EORTC; FACE;
D O I
10.1007/s00066-014-0627-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose. Wide surgical excision is the standard treatment for angiosarcoma of the scalp, but many patients are inoperable. Therefore, we investigated the outcome of radiation therapy for angiosarcoma of the scalp. Patients and methods. Seventeen patients with angiosarcoma of the scalp underwent radiation therapy with total scalp irradiation. Four patients had cervical lymph node metastases, but none had distant metastases. A median initial dose of 50 Gy in 25 fractions was delivered to the entire scalp. Subsequently, local radiation boost to the tumor sites achieved a median total dose of 70 Gy in 35 fractions. Results. Fourteen of the 17 patients developed recurrences during the median follow-up period of 14 months after radiation therapy; 7 had recurrences in the scalp, including primary tumor progression in 2 patients and new disease in 5, and 12 patients developed distant metastases. The primary progression-free, scalp relapse-free, and distant metastasis-free rates were 86, 67, and 38 % at 1 year and 86, 38, and 16 % at 3 years, respectively. Thirteen patients died; the overall and cause-specific survival rates were both 73 % at 1 year and 23 and 44 % at 3 years, respectively. The median survival time was 16 months. There were no therapy-related toxicities >= 3. Conclusion. Total scalp irradiation is safe and effective for local tumor control, but a dose of <= 50 Gy in conventional fractions may be insufficient to eradicate microscopic tumors. For gross tumors, a total dose of 70 Gy, and > 70 Gy for tumors with deep invasion, is recommended.
引用
收藏
页码:899 / 904
页数:6
相关论文
共 43 条
  • [1] Radiation Therapy for Angiosarcoma of the Scalp: Total Scalp Irradiation and Local Irradiation
    Hata, Masaharu
    ANTICANCER RESEARCH, 2018, 38 (03) : 1247 - 1253
  • [2] Radiation therapy for angiosarcoma of the scalpTreatment outcomes of total scalp irradiation with X-rays and electronsStrahlenbehandlung für Angiosarkome der KopfhautBehandlungsergebnisse einer Bestrahlung der gesamten Kopfhaut mit Röntgen- und Elektronenstrahlen
    Masaharu Hata
    Hidefumi Wada
    Ichiro Ogino
    Motoko Omura
    Izumi Koike
    Yoshibumi Tayama
    Kazumasa Odagiri
    Takeo Kasuya
    Tomio Inoue
    Strahlentherapie und Onkologie, 2014, 190 : 899 - 904
  • [3] Definitive Radiation Therapy for Angiosarcoma of the Face and Scalp
    Suzuki, Gen
    Yamazaki, Hideya
    Takenaka, Hideya
    Aibe, Norihiro
    Masui, Koji
    Kimoto, Takuya
    Tatekawa, Kotoha
    Nakashima, Akihiro
    Takenaka, Tadashi
    Asai, Jun
    Komori, Satoshi
    Wada, Makoto
    Katoh, Norito
    Yamada, Kei
    IN VIVO, 2016, 30 (06): : 921 - 926
  • [4] Clinical Outcomes of Radiation Therapy for Angiosarcoma of the Scalp and Face: A Multi-Institutional Observational Study
    Niwa, Masanari
    Tomita, Natsuo
    Takaoka, Taiki
    Takano, Hirota
    Makita, Chiyoko
    Matsuo, Masayuki
    Adachi, Sou
    Oshima, Yukihiko
    Yamamoto, Shintaro
    Kuno, Mayu
    Miyakawa, Akifumi
    Okazaki, Dai
    Torii, Akira
    Kita, Nozomi
    Takano, Seiya
    Nakamura, Motoki
    Kato, Hiroshi
    Morita, Akimichi
    Hiwatashi, Akio
    CANCERS, 2023, 15 (14)
  • [5] OUTCOMES AFTER DEFINITIVE TREATMENT FOR CUTANEOUS ANGIOSARCOMA OF THE FACE AND SCALP
    Guadagnolo, B. Ashleigh
    Zagars, Gunar K.
    Araujo, Dejka
    Ravi, Vinod
    Shellenberger, Thomas D.
    Sturgis, Erich M.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2011, 33 (05): : 661 - 667
  • [6] Proton Versus Intensity-Modulated Radiation Therapy: First Dosimetric Comparison for Total Scalp Irradiation
    Sharma, Ankur Markand
    Kowalski, Emily
    McGovern, Nathan
    Zhu, Mingyao
    Mishra, Mark Vikas
    INTERNATIONAL JOURNAL OF PARTICLE THERAPY, 2019, 6 (03): : 19 - 26
  • [7] Successful treatment of angiosarcoma of the scalp by intralesional cytokine therapy and surface irradiation
    Ulrich, J
    Krause, M
    Brachmann, A
    Franke, I
    Gollnick, H
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2000, 14 (05) : 412 - 415
  • [8] Clinical outcomes of scalp or face angiosarcoma treatment with intensity-modulated radiotherapy: a multicenter study
    Iwai, Takahiro
    Imagumbai, Toshiyuki
    Hiraoka, Shinya
    Kishi, Takahiro
    Okabayashi, Shun
    Ashida, Ryo
    Mitsuyoshi, Takamasa
    Matsuo, Yukinori
    Ishigaki, Takashi
    Mizowaki, Takashi
    Kokubo, Masaki
    JOURNAL OF RADIATION RESEARCH, 2023, : 78 - 86
  • [9] Fulminant course of angiosarcoma of the scalp on multimodal therapy with paclitaxel, bevacizumab, and radiation
    Darr-Foit, Susanne
    Goetze, Steven
    Elsner, Peter
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 (04): : 446 - 448
  • [10] Major response to paclitaxel combined with irradiation as second-line therapy in metastatic angiosarcoma of the face and scalp
    Hofmann, U. B.
    Wobser, M.
    Kneitz, H.
    Kleine, P.
    Becker, J. C.
    Brocker, E. B.
    Ugurel, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (02) : 456 - 458